| 2.11 -0.038 (-1.75%) | 04-06 10:37 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73  |
1-year : | 3.19 |
| Resists | First : | 2.33 |
Second : | 2.73 |
| Pivot price | 0.62 |
|||
| Supports | First : | 1.1 |
Second : | 0.34 |
| MAs | MA(5) : | 1.09 |
MA(20) : | 0.58 |
| MA(100) : | 0.54 |
MA(250) : | 0.73 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 81 |
D(3) : | 63.4 |
| RSI | RSI(14): 91.5 |
|||
| 52-week | High : | 2.33 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XRTX ] has closed above the upper band by 12.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1407.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.15 - 2.16 | 2.16 - 2.16 |
| Low: | 0.37 - 0.37 | 0.37 - 0.37 |
| Close: | 2.13 - 2.15 | 2.15 - 2.16 |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Fri, 03 Apr 2026
XRTX Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 01 Apr 2026
XORTX (XRTX) wins approvals for 1-for-5 share consolidation effective April 6, 2026 - Stock Titan
Wed, 01 Apr 2026
Every 5 XORTX shares become 1 on April 6 after approvals - Stock Titan
Wed, 01 Apr 2026
XORTX Confirms Effective Date of Share Consolidation - The Globe and Mail
Fri, 27 Mar 2026
XORTX Delays Effective Date of One-for-Five Share Consolidation - The Globe and Mail
Fri, 27 Mar 2026
XORTX Therapeutics (NASDAQ: XRTX) shareholders approve board, stock plan and share consolidation - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 10.2 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 94 (K) |
| Shares Short P.Month | 107 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.9 % |
| Return on Equity (ttm) | -98 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -3.74 |
| PEG Ratio | 0 |
| Price to Book value | 6.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|